UNSPSC 51111767: Vincristine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H56N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5J49Q6B70F, chemically known as vincaleukoblastine, 22-oxo- but generally known as vincristine, which bears US NIH Compound Identifier 5978. European Medicines Agency schedules Vincristine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00059MIG.

UNSPSC 51111767 Vincristine, a Commodity code, shows no relevant recent state and local procurement activity. The two most recently posted opportunities in the source—an Illinois Department of Public Health pharmaceutical piggyback contract for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (awarded to Chartwell Rx LLC in August 2026), and a Seminole County, Florida IFB for Naloxone and Drug Deactivation Systems (posted June 2026)—do not align with vincristine procurement. Vincristine is a chemotherapy agent typically used in cancer treatment and administered through specialized oncology supply chains and hospital pharmacy systems, whereas the flagged opportunities concern general antimicrobial pharmaceuticals and opioid-reversal medications for public health and community health programs.

The mismatch between code assignment and actual commodity suggests either miscategorization in the state and local procurement database or insufficient recent activity under this specific code to populate meaningful market signals. Business development professionals should verify directly with state health departments, hospital systems, cancer centers, and oncology pharmacy networks—not general pharmaceutical cooperative purchasing vehicles—for vincristine contracting opportunities. Without posted state and local solicitations under this code, forward pipeline visibility is not available from this source.